6 completed, 2 terminated. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Terminated 2 |
| Phase 2 | 1 | Completed 1 |
Follow crenigacestat: new trials by email Literature Review of crenigacestat trials Research Report on crenigacestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma BCMA-specific CAR-expressing T Lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 19 | 2018-05-23 | 2024-01-08 |
| A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors LY3039478, Taladegib, Abemaciclib - Solid Tumor, Breast Cancer | Phase 1 | Terminated | Eli Lilly and Company | 94 | 2016-11-04 | 2025-08-21 |
| Study of LY3039478 in Healthy Participants LY3039478, 13C 15N 2H-LY3039478 IV - Healthy | Phase 1 | Completed | Eli Lilly and Company | 12 | 2016-10-04 | 2025-07-09 |
| A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors LY3039478 - Advanced Solid Tumor | Phase 1 | Completed | Eli Lilly and Company | 11 | 2016-09-09 | 2025-08-07 |
| A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants LY3039478 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 6 | 2016-09-01 | 2025-07-28 |
| A Study of LY3039478 in Healthy Participants Placebo, LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1) - Healthy | Phase 1 | Completed | Eli Lilly and Company | 29 | 2016-01-01 | 2025-08-12 |
| A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL LY3039478, Dexamethasone, Placebo - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 36 | 2015-10-01 | 2019-09-11 |
| A Study of LY3039478 in Participants With Advanced Cancer LY3039478, Prednisone - Neoplasms, Neoplasm Metastasis | Phase 1 | Completed | Eli Lilly and Company | 247 | 2012-10-01 | 2025-12-26 |
Breast Neoplasms (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Lymphoma (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Sarcoma (1)
Eli Lilly and Company (7) · Fred Hutchinson Cancer Center (1)
United States (6) · France (3) · Denmark (2) · Germany (2) · Spain (2) · United Kingdom (2) · Israel (1) · Italy (1) · Japan (1)
Andrew Cowan (1)
PMID 30060061, PMID 30218977, PMID 31558469, PMID 32915419, PMID 32939607, PMID 33107983, PMID 33686452, PMID 36030462, PMID 37414012, PMID 40756609
2014 (1), 2015 (1), 2016 (1)